IntelliCyt

IntelliCyt developed and commercialized high-throughput suspension-cell analysis platforms—most notably the iQue Screener—for rapid phenotypic profiling in immunology, immuno-oncology, antibody discovery, and drug screening. Their technology enables faster and more cost-effective cell-based assays compared to traditional flow cytometry. The company was acquired by Sartorius in June 2016. No clinical results as it does not develop drugs. IntelliCyt was an innovative US-based biotechnology tools company specializing in high-throughput suspension-cell analysis platforms such as the iQue Screener system. Founded in Albuquerque in 2006 by R. Terry Dunlay, it enabled rapid phenotypic profiling critical to modern immunology/immuno-oncology drug discovery workflows through its unique integration of flow cytometry with automated sample handling. The company’s solutions became widely adopted across pharma/biotech industries before being acquired by Sartorius AG in June 2016 for $90 million USD—a move that expanded Sartorius’s portfolio into advanced cell analytics technologies essential for next-generation biologics R&D.